Fulcrum Therapeutics, Inc. - stock earnings
FULC Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -24.8 million USD | 871000 USD |
| 2023Q3 | -24.0 million USD | 759000 USD |
| 2023Q2 | -23.8 million USD | 880000 USD |
| 2023Q1 | -21.6 million USD | 295000 USD |
| 2022Q4 | -23.6 million USD | 685000 USD |
| 2022Q3 | -24.1 million USD | 1.2 million USD |
| 2022Q2 | -33.9 million USD | 1.9 million USD |
| 2022Q1 | -25.9 million USD | 2.6 million USD |
| 2021Q4 | -23.5 million USD | 5.1 million USD |
| 2021Q3 | -20.7 million USD | 4.9 million USD |
| 2021Q2 | -19.6 million USD | 4.4 million USD |
| 2021Q1 | -17.0 million USD | 4.8 million USD |
| 2020Q4 | -17.7 million USD | 4.2 million USD |
| 2020Q3 | -19.0 million USD | 1.8 million USD |
| 2020Q2 | -15.7 million USD | 2.0 million USD |
| 2020Q1 | -18.5 million USD | 750000 USD |
| 2019Q4 | -16.1 million USD | ? USD |
| 2019Q3 | -16.5 million USD | ? USD |
| 2019Q2 | -13.2 million USD | ? USD |
| 2019Q1 | -36.8 million USD | ? USD |
| 2018Q4 | -8.9 million USD | ? USD |
| 2018Q3 | -8.9 million USD | ? USD |
| 2018Q2 | -7.8 million USD | ? USD |
| 2018Q1 | -6.9 million USD | ? USD |
FULC Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -97.3 million USD | 2.8 million USD |
| 2022 | -105.6 million USD | 6.3 million USD |
| 2021 | -78.3 million USD | 19.2 million USD |
| 2020 | -68.4 million USD | 8.8 million USD |
| 2019 | -79.1 million USD | 750000 USD |
| 2018 | -32.6 million USD | ? USD |
| 2017 | -23.0 million USD | ? USD |
FULC
Price: $7.65
52 week price:
Earnings Per Share: -1.59 USD
P/E Ratio: -4.91
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 493900
Market Capitalization: 527.7 million